Combining Multiple Challenge Models Within A Single Individual: What Early Human Data Tells US

A single immune challenge can confirm functional activity, yet it rarely shows how broad, compartment-specific, or pathway-selective that activity is. Running separate local and systemic trials adds its own noise from differences in participants, exposure, timing, and assays.

This fifth installment in a series on early human data looks at what changes when complementary challenge models are combined within the same healthy participants. It draws on a randomised phase 1 study of two oral IRAK4 inhibitors and on further integrated designs, including cases where a null skin result did not mean absent pharmacology. It also addresses design cautions, from challenge order to multiplicity.

Read the article to see how the combined evidence reshaped interpretation and what it can and cannot support.